Literature DB >> 28146629

Identification of High-Potency Human TLR8 and Dual TLR7/TLR8 Agonists in Pyrimidine-2,4-diamines.

Mallesh Beesu1, Alex C D Salyer1, Michael J H Brush1, Kathryn L Trautman1, Justin K Hill1, Sunil A David1.   

Abstract

The induction of toll-like receptor 7 (TLR7)-dependent type I interferons (IFN-α/β) from plasmacytoid dendritic cells as well as the production of TLR8-dependent type II interferon (IFN-γ), TNF-α, and IL-12 in myeloid dendritic cells are of importance in generating T helper-1 biased adaptive immune responses. In an effort to identify novel dual TLR7/TLR8-active compounds, we undertook structure-activity relationship studies in pyrimidine 2,4-diamines, focusing on substituents at C5. Several analogues substituted with aminopropyl appendages at C5 displayed dominant TLR8-agonistic activity. N4-Butyl-6-methyl-5-(3-morpholinopropyl)pyrimidine-2,4-diamine was found to be a very potent dual TLR7/TLR8 agonist. Employing novel cytokine reporter cell assays, we verified that potency at TLR7 correlates with IFN-α/β production in human blood, whereas IFN-γ and TNF-α induction is largely TLR8-dependent. Dual TLR7/TLR8 agonists markedly upregulate CD80 expression in multiple dendritic cell subsets, providing insight into the immunological basis for the superior adjuvantic properties of such innate immune stimuli.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28146629     DOI: 10.1021/acs.jmedchem.6b01860

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

Review 1.  Targeting the innate immune receptor TLR8 using small-molecule agents.

Authors:  Kentaro Sakaniwa; Toshiyuki Shimizu
Journal:  Acta Crystallogr D Struct Biol       Date:  2020-06-17       Impact factor: 7.652

2.  High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens.

Authors:  Claudio Counoupas; Paco Pino; Alberto O Stella; Caroline Ashley; Hannah Lukeman; Nayan D Bhattacharyya; Takuya Tada; Stephanie Anchisi; Charles Metayer; Jacopo Martinis; Anupriya Aggarwal; Belinda M Dcosta; Warwick J Britton; Joeri Kint; Maria J Wurm; Nathaniel R Landau; Megan Steain; Stuart G Turville; Florian M Wurm; Sunil A David; James A Triccas
Journal:  Microbiol Spectr       Date:  2022-02-16

Review 3.  Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles.

Authors:  Deepender Kaushik; Arshpreet Kaur; Nikolai Petrovsky; Deepak B Salunke
Journal:  RSC Med Chem       Date:  2021-05-14

4.  BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant.

Authors:  Deepender Kaushik; Simran Dhingra; Madhuri T Patil; Sakshi Piplani; Varun Khanna; Yoshikazu Honda-Okubo; Lei Li; Johnson Fung; Isaac G Sakala; Deepak B Salunke; Nikolai Petrovsky
Journal:  Hum Vaccin Immunother       Date:  2020-04-16       Impact factor: 3.452

5.  Nasal Immunization With Small Molecule Mast Cell Activators Enhance Immunity to Co-Administered Subunit Immunogens.

Authors:  Brandi T Johnson-Weaver; Hae Woong Choi; Hang Yang; Josh A Granek; Cliburn Chan; Soman N Abraham; Herman F Staats
Journal:  Front Immunol       Date:  2021-09-10       Impact factor: 7.561

6.  Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors.

Authors:  Judith Stickdorn; Lara Stein; Danielle Arnold-Schild; Jennifer Hahlbrock; Carolina Medina-Montano; Joschka Bartneck; Tanja Ziß; Evelyn Montermann; Cinja Kappel; Dominika Hobernik; Maximilian Haist; Hajime Yurugi; Marco Raabe; Andreas Best; Krishnaraj Rajalingam; Markus P Radsak; Sunil A David; Kaloian Koynov; Matthias Bros; Stephan Grabbe; Hansjörg Schild; Lutz Nuhn
Journal:  ACS Nano       Date:  2022-02-01       Impact factor: 15.881

Review 7.  Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants.

Authors:  Sachin Bhagchandani; Jeremiah A Johnson; Darrell J Irvine
Journal:  Adv Drug Deliv Rev       Date:  2021-05-29       Impact factor: 15.470

8.  Squaric Ester-Based, pH-Degradable Nanogels: Modular Nanocarriers for Safe, Systemic Administration of Toll-like Receptor 7/8 Agonistic Immune Modulators.

Authors:  Anne Huppertsberg; Leonard Kaps; Zifu Zhong; Sascha Schmitt; Judith Stickdorn; Kim Deswarte; Francis Combes; Christian Czysch; Jana De Vrieze; Sabah Kasmi; Niklas Choteschovsky; Adrian Klefenz; Carolina Medina-Montano; Pia Winterwerber; Chaojian Chen; Matthias Bros; Stefan Lienenklaus; Niek N Sanders; Kaloian Koynov; Detlef Schuppan; Bart N Lambrecht; Sunil A David; Bruno G De Geest; Lutz Nuhn
Journal:  J Am Chem Soc       Date:  2021-06-24       Impact factor: 15.419

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.